Peter G. Traber

Professional Background

Peter has had a distinguished career in drug development, research, management, and governance, with demonstrated success in large matrix and small entrepreneurial organizations, including those in the pharmaceutical industry, biotechnology, academia, and healthcare. He is adept at strategic planning, designing and leading complex scientific and drug development programs, recruiting and leading effective executive teams, effecting and managing change efforts, building value, and effective communication. Prior to joining Alacrita, Peter was CEO and CMO of Galectin Therapeutics where he brought a galectin-3 inhibitor, a putative anti-fibrotic drug, from a research compound through development to a phase 3-ready program in NASH cirrhosis and built a pipeline of other indications. Before that in the pharmaceutical industry, he was Senior Vice President and CMO at GlaxoSmithKline where he had responsibility for a broad range of therapeutic areas.

In academic medicine, Peter ran a basic science laboratory program that made fundamental discoveries in liver and intestinal biology, and he served as Chief of Gastroenterology, Chairman of Medicine and CEO of the University of Pennsylvania School of Medicine and Health System. He also was President and CEO of Baylor College of Medicine. Peter has a BS degree in chemical engineering from the University of Michigan, an MD degree from Wayne State University School of Medicine, and a certificate in business leadership for physicians from The Wharton School.

Peter's Consulting Expertise

• Integrated therapeutic area and drug development strategy
  • Deep expertise in fibrosis, hepatology, and gastroenterology
• Innovative experimental medicine and clinical trial design and execution
• Scientific and clinical due diligence and drug positioning
  • Mechanism of action rationale, sequencing of disease indications, development and regulatory pathway strategy, and commercial positioning
• Chief Medical Officer strategies, roles, responsibilities, and execution
• Executive Officer, Board of Directors, and Scientific Advisory support
• Investor and market scientific communications

Peter Traber Blog Post Library

• Summer in Paris: NASH Update
• No Acceptable Surrogates for NASH Cirrhosis
• Therapy for NASH Cirrhosis is a Distant Hope
• Is Gilead’s Selonsertib for NASH Dead?
• NASH Surprises and Interpretation of Clinical Trials
• Agencies Clarify NASH Endpoints — But Don’t Harmonize
• Industry Strategies for NASH Combination Therapies
• Is Rapid Reversal of Liver Fibrosis Possible?
• Is Rapid Reversal of Liver Fibrosis Possible?
• NASH Cirrhosis Space Poised to Heat Up
• Madrigal’s and Viking’s NASH Drugs: Who’s best in class?
• NASH Bubble?
• Identifying Best Disease Indications for Anti-Fibrotic Drugs